Aggregatibacter actinomycetemcomitans, a Gram-negative bacterium, and Candida albicans, a polymorphic fungus, are both commensals of the oral cavity but both are opportunistic pathogens that can cause oral diseases. A. actinomycetemcomitans produces a quorum-sensing molecule called autoinducer-2 (AI-2), synthesized by LuxS, that plays an important role in expression of virulence factors, in intra- but also in interspecies communication. The aim of this study was to investigate the role of AI-2 based signaling in the interactions between C. albicans and A. actinomycetemcomitans. A. actinomycetemcomitans adhered to C. albicans and inhibited biofilm formation by means of a molecule that was secreted during growth. C. albicans biofilm formation increased significantly when co-cultured with A. actinomycetemcomitans luxS, lacking AI-2 production. Addition of wild-type-derived spent medium or synthetic AI-2 to spent medium of the luxS strain, restored inhibition of C. albicans biofilm formation to wild-type levels. Addition of synthetic AI-2 significantly inhibited hypha formation of C. albicans possibly explaining the inhibition of biofilm formation. AI-2 of A. actinomycetemcomitans is synthesized by LuxS, accumulates during growth and inhibits C. albicans hypha- and biofilm formation. Identifying the molecular mechanisms underlying the interaction between bacteria and fungi may provide important insight into the balance within complex oral microbial communities.

Provide evidence of success rate and limitations of the prehospital use of a powered device for intraosseous (IO) bone infusion, the bone injection gun (BIG) for critical patients in whom peripheral intravenous (IV) access cannot be readily obtained. This prospective study included all reports regarding the use of BIG in our national EMS during the study period. The BIG is a FDA and Israeli Health ministry approved device for IO cannulation. Starting April 2000, a new version was introduced to all ALS units. Simultaneously, our medical protocols were updated to include its use and mandatory reporting was initiated. Successful insertion was defined as “obtaining a good fluid flow through the needle without evidence of extravasation”. This article presents an analysis of the data collected during this period. From May 2000 to June 2004, 189 patient encounters in which the BIG was employed met inclusion criteria and comprised the study group. Successful insertion on first attempt was achieved in 172 patients (91.0%). In two additional patients, a second attempt was successful. Forty-seven of the patients were below the age of 18 years (24.9%). One hundred ten patients (58.2%) were over 60 years of age. One hundred thirty-three were found without a palpable pulse (70.4%), and only 18 were found with a Glasgow coma scale of 9 or above. The cause was traumatic in 34 patients (18.0%). The BIG provides an effective alternative IV access for critical patients in whom a peripheral IV line cannot be readily obtained in the prehospital setting.

Thrombin-related peptide 508 (TP508) accelerates bone regeneration during distraction osteogenesis (DO). We have examined the effect of TP508 on bone regeneration during DO by immunolocalization of Runx2 protein, a marker of osteoblast differentiation, and of osteopontin (OPN) and bone sialoprotein (BSP), two late markers of the osteoblast lineage. Distraction was performed in tibiae of rabbits over a period of 6 days. TP508 (30 or 300 μg) or vehicle was injected into the distraction gap at the beginning and end of the distraction period. Two weeks after active distraction, tissue samples were harvested and processed for immunohistochemical analysis. We also tested the in vitro effect of TP508 on Runx2 mRNA expression in osteoblast-like (MC3T3-E1) cells by polymerase chain reaction analysis. Runx2 and OPN protein were observed in preosteoblasts, osteoblasts, osteocytes of newly formed bone, blood vessel cells and many fibroblast-like cells of the soft connective tissue. Immunostaining for BSP was more restricted to osteoblasts and osteocytes. Significantly more Runx2- and OPN-expressing cells were seen in the group treated with 300 μg TP508 than in the control group injected with saline or with 30 μg TP508. However, TP508 failed to increase Runx2 mRNA levels significantly in MC3T3-E1 cells after 2–3 days of exposure. Our data suggest that TP508 enhances bone regeneration during DO by increasing the proportion of cells of the osteoblastic lineage. Clinically, TP508 may shorten the healing time during DO; this might be of benefit when bone regeneration is slow.